Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma A Randomized Trial
نویسندگان
چکیده
Original Research F patients with asthma who remain uncontrolled despite inhaled corticosteroid (ICS) therapy, a longacting inhaled b 2 -agonist (LABA) may be added. 1,2 Combination therapy improves symptoms, reduces severe exacerbation rate and achieves better asthma control in more patients than ICS monotherapy. 1,3-5 However, poor adherence to bid therapy may account for poor asthma control in some patients. For these patients, once-daily therapy could offer them greater convenience, thereby improving adherence. 6
منابع مشابه
Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma
BACKGROUND The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β2 agonist, is under development as a once-daily treatment of asthma and COPD. The aim of this study was to compare the efficacy of FF/VI with fluticasone propionate (FP)/salmeterol (SAL) in patients with persistent asthma uncontrolled on a medium dose of ICS. METHO...
متن کاملPatient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
OBJECTIVE Fluticasone furoate (FF), an inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting beta2 receptor agonist (LABA), is a new combination used in an Ellipta(®) device. This article compares FF-VI to other ICS-LABA combinations available, particularly emphasizing product selection from the patient perspective. DATA SOURCES A PubMED and EMBASE search completed in October 2015 ...
متن کاملInhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study
INTRODUCTION Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24-h activity. FF is in development as a once-daily treatment for asthma as monotherapy and in combination with vilanterol (VI), a long-acting β2 agonist. Corticosteroids can have systemic effects on hypothalamic-pituitary-adrenal (HPA) axis function, potentially resulting in cortisol suppression. OBJECTIVES To asses...
متن کاملEthnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials
BACKGROUND Fluticasone furoate (FF)/vilanterol (VI) is a once daily (OD) inhaled corticosteroid/long-acting β2-agonist combination asthma therapy approved in Japan and the EU. FF/VI efficacy and safety data from asthma studies including patients in East Asia were evaluated to assess ethnic sensitivity. METHODS Randomized, double-blind, multicenter Phase IIb/III trials were assessed. Change fr...
متن کاملFluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
BACKGROUND Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. OBJECTIVES To determine the optimal dose(s) of FF for treating patients with asthma. METHODS An 8-week multicentre, randomised, d...
متن کامل